Benzothiazole derivative bearing amide moiety induces p53-mediated apoptosis in HPV16 positive cervical cancer cells

SummaryIn our previous study, we screened the anti-cancer properties of 10 benzothiazole derivatives in cervical cancer cell lines. In the present study, we aimed to delineate the mechanism of the apoptotic pathway (whether intrinsic or extrinsic) following the treatment of N-(4-(benzo[d]thiazol-2-yl)phenyl)-5-chloro-2-methoxybenzamide (named as A-07) on cervical cancer cell lines. Cellular stress by reactive oxygen species was measured using DCFDA dye by flowcytometry. Protein expression and localization was checked by immunofluorescence for γH2A.X, TP53, and CASP-3. Expression profiles of BAX and BCL-2 was done by semi-quantitative RT-PCR and PARP-1 (Poly(ADP-ribose) polymerase-1) by Western blot analysis. Bioinformatic studies were done using PDB websites, metaPocket 2.0 server, YASARA software and Discovery Studio 3.5 Visualizer. We demonstrate that the compound A-07 leads to ROS generation and double strand breaks in SiHa and C-33A cells. The induction of apoptosis in SiHa cells is associated with increased nuclear expression of the tumor suppressor protein, TP53. The shift in BAX/BCL-2 ratio, increased expression of Caspase- 3 and cleaved Poly(ADP-ribose) polymerase-1 favour apoptotic signal in SiHa. In silico studies revealed that A-07 has inhibiting capabilities to the E6/E6AP/P53 complex. Our data suggest that treatment of A-07 causes p53 and caspase dependent apoptosis in HPV 16 infected SiHa cells.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research

Related Links:

MONDAY, Aug. 2, 2021 -- The COVID-19 pandemic significantly disrupted breast, colorectal, and cervical cancer screenings among patients at federally qualified health centers (FQHCs), according to a study published online June 30 in Preventive...
Source: - Pharma News - Category: Pharmaceuticals Source Type: news
CONCLUSIONS: There was no evidence that a single message used to convey social norms, outcome expectancy, risk reduction or response efficacy had an impact on intention strength for older women who did not plan to be screened in future.PMID:34339562 | DOI:10.1111/bjhp.12552
Source: British Journal of Health Psychology - Category: Psychiatry & Psychology Authors: Source Type: research
Cancer Biomark. 2021 Jul 23. doi: 10.3233/CBM-201021. Online ahead of print.ABSTRACTBACKGROUND: MicroRNAs (miRNA) are promising biomarkers for cancer diagnosis and prognosis; miR-100 expression is decreased in cervical cancer tissues.OBJECTIVE: To determine whether miR-100 is a useful biomarker for early cervical cancer diagnosis.METHODS: Total RNA was extracted from the sera of 34 healthy controls (HC), 64 cervical intraepithelial neoplasia patients (CIN), and 46 cervical cancer patients (CC). miR-100 expression levels were measured with quantitative real-time PCR. Correlations between clinicopathological factors and miR-...
Source: Cancer Biomarkers - Category: Cancer & Oncology Authors: Source Type: research
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
The purpose of study is to measure Point A pear-shaped isodose dimensions of the conventional intracavitary brachytherapy with various sizes of colpostats and analyze which size of tumor is the optimal for 3-D interstitial brachytherapy. CT simulation was performed with Fletcher type applicator using various sizes of colpostats (2.0, 2.5, and 3.0 cm diameter). The Manchester standard loading (dwell time) system was used to generate pear-shaped isodose envelopes with high-dose rate iridium-192 according to the colpostat sizes.
Source: Medical Dosimetry - Category: Radiology Authors: Source Type: research
Cervical cancer (CC) is the third leading cause of cancer among women worldwide, and also is the 16th cause of female cancer among Iranian people (Taebi et al., 2019). Approximately, 570,000 new cases and 310,000 deaths of CC have been estimated annually around the world (Wang et al., 2019). Viral infections, especially human papillomavirus infection (HPV) which is recognized as one of the most common sexually transmitted infections worldwide, are now one of the known risk factors for CC (Nishimura et al., 2021), i.e., CC is by far the most frequent HPV-related disease (Xing et al., 2021).
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research
Human papilloma viruses (HPV) are small epitheliotropic DNA viruses, of which there are 200 genotypes, 40 of which are known to cause genital infections and are also oncogenic. HPV is the most common sexually transmitted infection. Clinical features vary from asymptomatic (identified at routine cervical cancer screening) to large lesions on the vulva, vagina, cervix and some extragenital sites. Its prevalence in pregnancy varies from 5.5%-65% depending on age, geography and gestational age (increasing with gestational age).
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - Category: OBGYN Authors: Tags: Full length article Source Type: research
We present 20 years of experience with two-step less radical fertility-sparing surgery in women with IA1, LVSI positive, IA2 and IB1 (
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: Our findings show that PSMA expression was present in two-thirds of patients with neck PRD, that it was related to poor prognostic factors and that very high expression was associated with poorer PFS. This preliminary study may offer new perspectives for the management of RAI-refractory DTC.PMID:34331544 | DOI:10.1210/clinem/dgab563
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Source Type: research
In conclusion, vorinostat reverses epithelial-mesenchymal transition by targeting UBE2C and controls the proliferation of cervical cancer cells through the ubiquitination pathway. UBE2C can be used as a promising target for the development of vorinostat treatment strategies.PMID:34331954 | DOI:10.1016/j.ejphar.2021.174399
Source: European Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Cervical Cancer | Drugs & Pharmacology | Investigational New Drugs | Study | Websites